Research delivers insight into the Schizophrenia - Pipeline Review, H1 2017
Schizophrenia - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.
Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.
Complete report available @ Schizophrenia - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 12, 13, 22, 1, 54, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 9 and 2 molecules, respectively.
Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
- The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Acadia Pharmaceuticals Inc Adamed Sp z oo Aequus Pharmaceuticals Inc AgeneBio Inc Alkermes Plc Angita BV Astellas Pharma Inc Athersys Inc Avanir Pharmaceuticals Inc Avineuro Pharmaceuticals Inc BCWorld Pharm Co Ltd BioCrea GmbH BioHealthonomics Inc Boehringer Ingelheim GmbH Braeburn Pharmaceuticals Inc Bristol-Myers Squibb Company Critical Pharmaceuticals Ltd Curemark LLC Daewoong Pharmaceutical Co Ltd Delpor Inc Denovo Biopharma LLC Evotec AG F. Hoffmann-La Roche Ltd Fabre-Kramer Pharmaceuticals Inc Galenea Corp GeNeuro SA GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd GP Pharm SA GW Pharmaceuticals Plc H. Lundbeck A/S Heptares Therapeutics Ltd Hisamitsu Pharmaceutical Co Inc Indivior Plc Insys Therapeutics Inc IntelGenx Corp Intra-Cellular Therapies Inc Johnson & Johnson JT Pharmaceuticals Inc Karuna Pharmaceuticals Inc KemPharm Inc Kowa Company Ltd Laboratorios Farmaceuticos Rovi SA Lead Discovery Center GmbH Lohocla Research Corp Luye Pharma Group Ltd Mapi Pharma Ltd Merck & Co Inc Mitsubishi Tanabe Pharma Corp Neurocrine Biosciences Inc NeurOp Inc Newron Pharmaceuticals SpA Omeros Corp Otsuka Holdings Co Ltd Peptron Inc Pfizer Inc Promentis Pharmaceuticals Inc Ra Pharmaceuticals Inc Reviva Pharmaceuticals Inc Richter Gedeon Nyrt Sage Therapeutics Inc SK Biopharmaceuticals Co Ltd Sumitomo Dainippon Pharma Co Ltd Sunovion Pharmaceuticals Inc Suven Life Sciences Ltd Taisho Pharmaceutical Holdings Co Ltd Tetra Discovery Partners LLC Teva Pharmaceutical Industries Ltd Vanda Pharmaceuticals Inc Vitality Biopharma Inc VLP Therapeutics LLC Zogenix Inc Zysis Ltd
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research
###
posted by Reportstack @ 07:25
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home